VIDEO: Treating prostate cancer in older men with next generation therapy plus upfront ADT
Click Here to Manage Email Alerts
In this video, Daniel P. Petrylak, MD, discussed a presentation investigating androgen deprivation therapy plus upfront docetaxel in the treatment of patients 75 years or older with prostate cancer.
The findings were presented the American Urological Association meeting in New Orleans.
“One of the things that’s concerned me most about the treatment of men with hormone-sensitive prostate cancer is the fact that the use of other treatments in addition to androgen deprivation therapy, such as abiraterone [Yonsa, Sun Pharmaceutical Industries], enzalutamide [Xtandi; Astellas Oncology, Pfizer], adalimumab [Humira, AbbVie], docetaxel, and now daralutamide [Nubeqa, Pfizer]have not really caught on,” Petrylak, professor of medicine and urology at Yale University and co-leader of the Cancer Signaling Networks at Yale Cancer Center, said. “In fact, there are some studies that say that only about 50% of patients do receive next-generation treatment in addition to their upfront treatment with androgen deprivation therapy.”
Reference
- Hatakeyama S, et al. The impact of older age on the oncological outcomes for high-risk metastatic hormone-sensitive prostate cancer treated with upfront intensive therapy. Presented at: American Urological Association meeting; May 13-16, 2022 (hybrid meeting).
Collapse
Healio Interviews
Click Here to Manage Email Alerts